Data presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tailoring biologic treatment to individual patients with rheumatoid arthritis (RA) can reduce total costs by 2,595,557 euros per 272 patients over 3 years (95 percentile range -2,983,760 to -2,211,755 euros), whilst increasing effectiveness by an average of 3.67 quality-adjusted life years (QALYs)*. Cost savings were mostly on drug costs...
Realtime Related Tweets
invalid username or userid in get_avatar
joan crawford john goodman kendall marshall whitney houston news sylvia plath whitney houston whitney houston autopsy results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.